Fed. Circ. Urged Not To Review Venue In $20M Cialis IP Row

By Tiffany Hu (January 22, 2019, 3:40 PM EST) -- A German pharmaceutical company has urged the Federal Circuit not to rehear a panel decision that upheld a $20 million Eastern District of Texas jury verdict that Eli Lilly and Co.'s Cialis drug infringed its patent, saying that Lilly lost its chance to make validity and venue challenges by not raising them earlier....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!